CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating expenses:
Research and development	$ 4,911	$ 3,111
General and administrative	2,140	1,243
Total operating expenses	7,051	4,354
Loss from operations	(7,051)	(4,354)
Interest income	247	275
Other expense		(5,500)
Net loss	$ (6,804)	$ (9,579)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.73)	$ (3.72)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.73)	$ (3.72)
Weighted-average common shares outstanding, basic (in shares)	9,381,344	2,575,462
Weighted-average common shares outstanding, diluted (in shares)	9,381,344	2,575,462
Comprehensive loss:
Net loss	$ (6,804)	$ (9,579)
Unrealized (loss) gain on short-term investments	(7)	2
Comprehensive loss	$ (6,811)	$ (9,577)